Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

被引：64
|
作者：
Cousin, S. [1 ,2 ]
Toulmonde, M. [1 ,2 ]
Kind, M. [3 ]
Cazeau, A. -L. [4 ]
Bechade, D. [2 ]
Coindre, J. -M. [5 ]
Italiano, A. [1 ,2 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[2] Inst Bergonie, Dept Med, Bordeaux, France
[3] Inst Bergonie, Dept Radiol, Bordeaux, France
[4] Inst Bergonie, Dept Nucl Med, Bordeaux, France
[5] Inst Bergonie, Dept Pathol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期
关键词：
METASTATIC MELANOMA; IPILIMUMAB; PATIENT;
D O I：
10.1093/annonc/mdw125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [21] Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
    Mamesaya, Nobuaki
    Kenmotsu, Hirotsugu
    Katsumata, Mineo
    Nakajima, Takashi
    Endo, Masahiro
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 105 - 107
  • [22] Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma
    Thoreau, Benjamin
    Gouaillier-Vulcain, Flora
    Machet, Laurent
    Mateus, Christine
    Robert, Caroline
    Ferreira-Maldent, Nicole
    Maillot, Francois
    Lioger, Bertrand
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) : 408 - 409
  • [23] Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
    Nobuaki Mamesaya
    Hirotsugu Kenmotsu
    Mineo Katsumata
    Takashi Nakajima
    Masahiro Endo
    Toshiaki Takahashi
    Investigational New Drugs, 2017, 35 : 105 - 107
  • [24] A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605)
    Luke, Jason J.
    Chmura, Steven J.
    Allred, Jacob B.
    Salama, Joseph Kamel
    Al-Hallaq, Hania A.
    Hsu, Charles
    Yom, Sue S.
    Kozloff, Mark
    Munster, Pamela N.
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.
    Burgess, Melissa Amber
    Crowley, John
    Reinke, Denise K.
    Riedel, Richard F.
    George, Suzanne
    Movva, Sujana
    Van Tine, Brian Andrew
    Davis, Lara Emily
    Schuetze, Scott
    Hu, James
    Attia, Steven
    Priebat, Dennis A.
    Reed, Damon R.
    D'Angelo, Sandra P.
    Okuno, Scott H.
    Maki, Robert G.
    Patel, Shreyaskumar
    Baker, Laurence H.
    Tawbi, Hussein Abdul-Hassan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD1 monoclonal antibody, in patients with advanced malignancies
    Song, Xuyang
    Gao, Xizhe
    Zheng, Bo
    Black, Chelsea
    Gribbin, Matthew
    Karakunnel, Joyson
    Roskos, Lorin
    Narwal, Rajesh
    CANCER RESEARCH, 2017, 77
  • [27] Acute onset Type 1 diabetes precipitated by Pembrolizumab, an anti-PD-1 monoclonal antibody used as a treatment for melanoma
    Farrell, C. M.
    Casasola, R.
    Pearson, E. Z.
    Schofield, C.
    DIABETIC MEDICINE, 2017, 34 : 95 - 95
  • [28] Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab
    Park, Daniel
    Airi, Rany
    Sherman, Michael
    BMJ CASE REPORTS, 2020, 13 (09)
  • [29] TOLERANCE AND OUTCOMES OF STEREOTACTIC RADIOSURGERY COMBINED WITH ANTI-PD1 (PEMBROLIZUMAB) FOR MELANOMA BRAIN METASTASES
    Nardin, Charlee
    Mateus, Christine
    Texier, Matthieu
    Lanoy, Emilie
    Hibat-Allah, Salima
    Ammari, Sami
    Robert, Caroline
    Dhermain, Frederic
    NEURO-ONCOLOGY, 2017, 19 : 43 - 43
  • [30] Tolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma brain metastases
    Nardin, C.
    Mateus, C.
    Texier, M.
    Lanoy, E.
    Hibat-Allah, S.
    Ammari, S.
    Robert, C.
    Dhermain, F.
    ANNALS OF ONCOLOGY, 2017, 28
12345